Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.
Many efforts to reduce prostate specific antigen (PSA) overdiagnosis and overtreatment have been made. To this aim, Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) have been proposed as new more specific biomarkers. We evaluated the ability of phi and PCA3 to identify prostate cance...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3701535?pdf=render |
id |
doaj-34e7db0519504e5aa7da1b8a4d712784 |
---|---|
record_format |
Article |
spelling |
doaj-34e7db0519504e5aa7da1b8a4d7127842020-11-25T02:32:27ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0187e6768710.1371/journal.pone.0067687Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.Matteo FerroDario BruzzeseSisto PerdonàAda MarinoClaudia MazzarellaGiuseppe PerruoloVittoria D'EspositoVincenzo CosimatoCarlo BuonerbaGiuseppe Di LorenzoGennaro MusiOttavio De CobelliFelix K ChunDaniela TerraccianoMany efforts to reduce prostate specific antigen (PSA) overdiagnosis and overtreatment have been made. To this aim, Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) have been proposed as new more specific biomarkers. We evaluated the ability of phi and PCA3 to identify prostate cancer (PCa) at initial prostate biopsy in men with total PSA range of 2-10 ng/ml. The performance of phi and PCA3 were evaluated in 300 patients undergoing first prostate biopsy. ROC curve analyses tested the accuracy (AUC) of phi and PCA3 in predicting PCa. Decision curve analyses (DCA) were used to compare the clinical benefit of the two biomarkers. We found that the AUC value of phi (0.77) was comparable to those of %p2PSA (0.76) and PCA3 (0.73) with no significant differences in pairwise comparison (%p2PSA vs phi p = 0.673, %p2PSA vs. PCA3 p = 0.417 and phi vs. PCA3 p = 0.247). These three biomarkers significantly outperformed fPSA (AUC = 0.60), % fPSA (AUC = 0.62) and p2PSA (AUC = 0.63). At DCA, phi and PCA3 exhibited a very close net benefit profile until the threshold probability of 25%, then phi index showed higher net benefit than PCA3. Multivariable analysis showed that the addition of phi and PCA3 to the base multivariable model (age, PSA, %fPSA, DRE, prostate volume) increased predictive accuracy, whereas no model improved single biomarker performance. Finally we showed that subjects with active surveillance (AS) compatible cancer had significantly lower phi and PCA3 values (p<0.001 and p = 0.01, respectively). In conclusion, both phi and PCA3 comparably increase the accuracy in predicting the presence of PCa in total PSA range 2-10 ng/ml at initial biopsy, outperforming currently used %fPSA.http://europepmc.org/articles/PMC3701535?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Matteo Ferro Dario Bruzzese Sisto Perdonà Ada Marino Claudia Mazzarella Giuseppe Perruolo Vittoria D'Esposito Vincenzo Cosimato Carlo Buonerba Giuseppe Di Lorenzo Gennaro Musi Ottavio De Cobelli Felix K Chun Daniela Terracciano |
spellingShingle |
Matteo Ferro Dario Bruzzese Sisto Perdonà Ada Marino Claudia Mazzarella Giuseppe Perruolo Vittoria D'Esposito Vincenzo Cosimato Carlo Buonerba Giuseppe Di Lorenzo Gennaro Musi Ottavio De Cobelli Felix K Chun Daniela Terracciano Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. PLoS ONE |
author_facet |
Matteo Ferro Dario Bruzzese Sisto Perdonà Ada Marino Claudia Mazzarella Giuseppe Perruolo Vittoria D'Esposito Vincenzo Cosimato Carlo Buonerba Giuseppe Di Lorenzo Gennaro Musi Ottavio De Cobelli Felix K Chun Daniela Terracciano |
author_sort |
Matteo Ferro |
title |
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. |
title_short |
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. |
title_full |
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. |
title_fullStr |
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. |
title_full_unstemmed |
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. |
title_sort |
prostate health index (phi) and prostate cancer antigen 3 (pca3) significantly improve prostate cancer detection at initial biopsy in a total psa range of 2-10 ng/ml. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
Many efforts to reduce prostate specific antigen (PSA) overdiagnosis and overtreatment have been made. To this aim, Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) have been proposed as new more specific biomarkers. We evaluated the ability of phi and PCA3 to identify prostate cancer (PCa) at initial prostate biopsy in men with total PSA range of 2-10 ng/ml. The performance of phi and PCA3 were evaluated in 300 patients undergoing first prostate biopsy. ROC curve analyses tested the accuracy (AUC) of phi and PCA3 in predicting PCa. Decision curve analyses (DCA) were used to compare the clinical benefit of the two biomarkers. We found that the AUC value of phi (0.77) was comparable to those of %p2PSA (0.76) and PCA3 (0.73) with no significant differences in pairwise comparison (%p2PSA vs phi p = 0.673, %p2PSA vs. PCA3 p = 0.417 and phi vs. PCA3 p = 0.247). These three biomarkers significantly outperformed fPSA (AUC = 0.60), % fPSA (AUC = 0.62) and p2PSA (AUC = 0.63). At DCA, phi and PCA3 exhibited a very close net benefit profile until the threshold probability of 25%, then phi index showed higher net benefit than PCA3. Multivariable analysis showed that the addition of phi and PCA3 to the base multivariable model (age, PSA, %fPSA, DRE, prostate volume) increased predictive accuracy, whereas no model improved single biomarker performance. Finally we showed that subjects with active surveillance (AS) compatible cancer had significantly lower phi and PCA3 values (p<0.001 and p = 0.01, respectively). In conclusion, both phi and PCA3 comparably increase the accuracy in predicting the presence of PCa in total PSA range 2-10 ng/ml at initial biopsy, outperforming currently used %fPSA. |
url |
http://europepmc.org/articles/PMC3701535?pdf=render |
work_keys_str_mv |
AT matteoferro prostatehealthindexphiandprostatecancerantigen3pca3significantlyimproveprostatecancerdetectionatinitialbiopsyinatotalpsarangeof210ngml AT dariobruzzese prostatehealthindexphiandprostatecancerantigen3pca3significantlyimproveprostatecancerdetectionatinitialbiopsyinatotalpsarangeof210ngml AT sistoperdona prostatehealthindexphiandprostatecancerantigen3pca3significantlyimproveprostatecancerdetectionatinitialbiopsyinatotalpsarangeof210ngml AT adamarino prostatehealthindexphiandprostatecancerantigen3pca3significantlyimproveprostatecancerdetectionatinitialbiopsyinatotalpsarangeof210ngml AT claudiamazzarella prostatehealthindexphiandprostatecancerantigen3pca3significantlyimproveprostatecancerdetectionatinitialbiopsyinatotalpsarangeof210ngml AT giuseppeperruolo prostatehealthindexphiandprostatecancerantigen3pca3significantlyimproveprostatecancerdetectionatinitialbiopsyinatotalpsarangeof210ngml AT vittoriadesposito prostatehealthindexphiandprostatecancerantigen3pca3significantlyimproveprostatecancerdetectionatinitialbiopsyinatotalpsarangeof210ngml AT vincenzocosimato prostatehealthindexphiandprostatecancerantigen3pca3significantlyimproveprostatecancerdetectionatinitialbiopsyinatotalpsarangeof210ngml AT carlobuonerba prostatehealthindexphiandprostatecancerantigen3pca3significantlyimproveprostatecancerdetectionatinitialbiopsyinatotalpsarangeof210ngml AT giuseppedilorenzo prostatehealthindexphiandprostatecancerantigen3pca3significantlyimproveprostatecancerdetectionatinitialbiopsyinatotalpsarangeof210ngml AT gennaromusi prostatehealthindexphiandprostatecancerantigen3pca3significantlyimproveprostatecancerdetectionatinitialbiopsyinatotalpsarangeof210ngml AT ottaviodecobelli prostatehealthindexphiandprostatecancerantigen3pca3significantlyimproveprostatecancerdetectionatinitialbiopsyinatotalpsarangeof210ngml AT felixkchun prostatehealthindexphiandprostatecancerantigen3pca3significantlyimproveprostatecancerdetectionatinitialbiopsyinatotalpsarangeof210ngml AT danielaterracciano prostatehealthindexphiandprostatecancerantigen3pca3significantlyimproveprostatecancerdetectionatinitialbiopsyinatotalpsarangeof210ngml |
_version_ |
1724819148410716160 |